Celecoxib Efficacy And Safety Versus Diclofenac In Acute Pain Due To Cervical Sprain Related To A Traffic Accident

Phase 4

Terminated

• Conditions: Pain
• Interventions: Drug: oral Diclofenac; Drug: Celecoxib

• Registration Number: NCT00894790
• Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Brief Summary

This Study Will Evaluate Celecoxib Efficacy And Safety Versus Standard Doses Of Diclofenac In Acute Pain Due To Cervical Injury (Due To A Sprain) Related To A Motor Vehicle Accident

Detailed Description

On 21Oct2010 study was prematurely terminated due to poor enrollment with subsequent low number of participants. No safety or efficacy issues were involved in the decision to terminate prematurely.

Study Timeline

• Study First Submitted: 2009-03-27
• Study First Submitted QC: 2009-05-06
• Study First Posted: 2009-05-07
• Study Start: 2009-11
• Primary Completion: 2010-01
• Study Completion: 2010-01
• Results First Submitted: 2011-01-28
• Results First Submitted QC: 2011-01-31
• Results First Posted: 2011-02-25
• Status Verified: 2021-01
• Last Update Submitted: 2021-01-29
• Last Update Posted: 2021-02-02

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

• Patients That Had Suffered A Car Accident And Due To It Suffered A Cervical Sprain

Exclusion Criteria

• Recent Cervical Sprains Or Other Cervical Conditions

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
2	oral Diclofenac	-
1	Celecoxib	-

Primary Outcome Measures

Name	Time	Method
Change From Baseline to Day 7 of Participant's Assessment of Cervical Pain Due to Cervical Sprain	Baseline, Day 7	Participant rated visual analogue scale (VAS) for pain ranging from 0 to 100 mm (no pain to worst possible pain).

Secondary Outcome Measures

Name	Time	Method
Modified Brief Pain Inventory-Short Form (m-BPI-sf): Pain Severity Index Scores	Baseline, Days 7, 14	m-BPI-sf: participant rated 11-point Likert rating scale ranging from 0 (no pain) to 10 (worst pain possible). Pain severity index is the mean of item scores 2, 3, and 4 (pain right now, worst pain, and average pain level).
Change From Baseline in Categorical Responses to Participant's Gastrointestinal (GI) Symptom Questionnaire	Baseline, Days 7, 14	Two part questionnaire; First part assessed symptoms: feeling of gas/air in stomach or feeling bloated, nausea, vomiting, excessive burping or belching and worsening of heartburn or acid reflux. Participant rated Yes/No experienced, for how many days per week (1 through 7) for each symptom and how bothered they were (not at all, somewhat or very). Second part assessed the presence of general abdominal pain (steady, dull, sharp/shooting, always present or comes and goes), the number of days they experienced it (1 through 7) and how bothered they were by it (not at all, somewhat, very).
Percentage of Participants With at Least a 20 mm Improvement on VAS-pain (Responder Rates)	Baseline, Days 7, 14	Participant rated visual analogue scale (VAS) for pain ranging from 0 to 100 mm (no pain to worst possible pain) with at least a 20 mm improvement.
Change From Baseline in Patient Global Assessment of Cervical Injury	Baseline, Days 7, 14	Participant rated responses to question: Considering all the ways your cervical injury affects you, how are you doing today? Response options ranged from 1 (Very good - No symptoms and no limitation of normal activities) to 5 (Very Poor - Very severe symptoms which are intolerable and inability to carry out all normal activities).
Change From Baseline in Modified Brief Pain Inventory-Short From (m-BPI-sf): Pain Interference Score	Baseline, Days 7, 14	m-BPI-sf: participant-rated 11 point Likert rating scale ranging from 0 (does not interfere) to 10 (completely intereres) with functional activities (general activity, mood, walking ability, relations with other people, sleep, normal work, and enjoyment of life) in past 24 hours.
Change From Baseline on VAS-pain at Day 3 and Day 14	Baseline, Days 3, 14	Participant rated visual analogue scale (VAS) for pain ranging from 0 to 100 mm (no pain to worst possible pain).
Change From Baseline on Physician's Global Assessment of Cervical Injury	Baseline, Days 7, 14	Physician rated responses evaluating the overall condition of participant's cervical injury at that time. Response option ranged from 1 (Very mild - Very mild signs and symptoms of cervical injury) to 5 (Very Severe - Very severe signs and symptoms of cervical injury).
Change From Baseline in Participant's Responses to Neck Disability Index (NDI)	Baseline, Days 7, 14	NDI: participant-administered 10-item questionnaire to assess how neck pain affects 10 activities of daily living (pain intensity, personal care, lifting, reading, headaches, concentration, work, driving, sleeping, and recreation) with six potential responses, each describing a greater degree of disability (0 = no disability to 5 = total disability). Total score calculated by adding individual item scores for evaluation scheme: 0-5 = No disability; 6-15 = Mild disability; 16-25 = Moderate disability; 26-35 = Severe disability; Above 35 = Complete disability.

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇲🇽 Mexico, D.f., Mexico